Evidence map›Paper›PMID 32085742›Full record

ArticleHarm reduction journal2020

Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey.

Luk Van Baelen, Els Plettinckx, Jérôme Antoine, Lies Gremeaux

Abstract read
In one paragraph

Article in Harm reduction journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Dependence-Robust Confidence Intervals for Capture-Recapture Surveys.Journal of survey statistics and methodology · 2023
    Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luk Van BaelenSciensano, Rue Juliette Wytsmanstraat, 14, 1050, Brussels, Belgium. luk.vanbaelen@sciensano.be.ORCID 0000-0003-2119-7255
Els PlettinckxSciensano, Rue Juliette Wytsmanstraat, 14, 1050, Brussels, Belgium.
Jérôme AntoineSciensano, Rue Juliette Wytsmanstraat, 14, 1050, Brussels, Belgium.
Lies GremeauxSciensano, Rue Juliette Wytsmanstraat, 14, 1050, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Belgium, people who inject drugs (PWID) are at a high risk of being infected by hepatitis C (HCV) as injecting drug use is the main mode for transmission of HCV in Europe. Estimates about the number of people living with HCV in Belgium are rare and even less is known about the prevalence of HCV among PWID.

methodBetween 1 February 2019 and 26 April 2019, PWID and high-risk opiate users (HROU) were recruited in Brussels through respondent-driven sampling (RDS). They were invited to a questionnaire and underwent a rapid HCV test.

resultsA total of 253 respondents participated in the study, of which 168 were PWID and 238 were HROU, with 153 respondents belonging to both categories. The overall unweighted sample average for HCV antibodies was 41.1%. The weighted population estimates were 43.7% (95% CI 30.6-56.8%) for RDS-II and 43.4% (95% CI 28.9-58.0%) for RDS-SS.

conclusionsThis prevalence is lower than the prevalence estimates reported elsewhere in Europe. However, the data still suggest that serious efforts are needed to reach the goal set by the WHO to reduce HCV by 2030 with 90%.

Indexed as

AdultBelgiumComorbidityDrug UsersFemaleHepatitis CHumansMalePrevalenceSubstance Abuse, IntravenousBelgiumHepatitis CPeople who inject drugsPrevalence

Identifiers

PMID32085742
PMCPMC7035658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.